Cost-effectiveness analysis of apixaban compared to other direct oral anticoagulants for prevention of stroke in Austrian atrial fibrillation patients

References

• Andresen K, Atar D, Gjertsen E, et al. Mechanisms of action and clinical use of specific reversal agents for non-vitamin K antagonist oral anticoagulants. Scand Cardiovasc J. 2018;52(3):156–162. DOI:10.1080/14017431.2018.1453613.
   PubMed Web of Science ®Google Scholar
• Wilke T, Groth A, Mueller S, et al., Incidence and prevalence of atrial fibrillation: an analysis based on 8.3 million patients. Europace. 15(4): 486–493. 2013. DOI: 10.1093/europace/eus333.
   PubMed Web of Science ®Google Scholar
• Kompetenznetz Vorhofflimmern. Vorhofflimmern frühzeitig erkennen: Viele Schlaganfälle wären vermeidbar [Early detection of atrial fibrillation: Many strokes would be avoidable]. 2010 [cited 2019 May 28]. Available from https://www.kompetenznetz-vorhofflimmern.de/de/vorhofflimmern-fruehzeitig-erkennen-viele-schlaganfaelle-waeren-vermeidbar. German.
   Google Scholar
• de Jong LA, Groeneveld J, Stevanovic J, et al. Cost-effectiveness of apixaban compared to other anticoagulants in patients with atrial fibrillation in the real-world and trial settings. PLoS One. 2019 Sep;14(9):e0222658. DOI:10.1371/journal.pone.0222658.
   PubMed Web of Science ®Google Scholar
• Maura G, Billionnet C, Drouin J, et al. Oral anticoagulation therapy use in patients with atrial fibrillation after the introduction of non-vitamin K antagonist oral anticoagulants: findings from the French healthcare databases, 2011–2016. BMJ Open. 2019;9:e026645.
   PubMed Web of Science ®Google Scholar
• Saraiva JFK. Stroke Prevention with Oral Anticoagulants: Summary of the Evidence and Efficacy Measures as an Aid to Treatment Choices. Cardiol Ther. 2018 Jun;7(1):15–24.
   PubMed Web of Science ®Google Scholar
• Kirchhof P, Benussi S, Kotecha D, et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J. 2016 Oct;37(38):2893–2962.
   PubMed Web of Science ®Google Scholar
• Camm AJ, Lip GY, De Caterina R, et al. ESC Committee for Practice Guidelines (CPG). 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association. Eur Heart J. 2012 Nov;33(21):2719–2747. DOI:10.1093/eurheartj/ehs253.
   PubMed Web of Science ®Google Scholar
• European Medicines Agency (EMA). Product-information Eliquis. 2016 Jan 14 [cited 2020 Feb 10]. https://www.ema.europa.eu/en/documents/product-information/eliquis-epar-product-information_en.pdf.
   Google Scholar
• Granger CB, Alexander JH, McMurray JJV, et al. ARISTOTLE Committees and Investigators. Apixaban versus Warfarin in Patients with Atrial Fibrillation. N Engl J Med. 2011 Sep;365(11):981–992. DOI:10.1056/NEJMoa1107039.
   PubMed Web of Science ®Google Scholar
• Connolly SJ, Eikelboom J, Joyner C, et al. AVERROES Steering Committee and Investigators. Apixaban in patients with atrial fibrillation. N Engl J Med. 2011 Mar;364(9):806–817. DOI:10.1056/NEJMoa1007432.
   PubMed Web of Science ®Google Scholar
• Pinyol C, Cepeda JM, Roldan I, et al. A Systematic Literature Review on the Cost-Effectiveness of Apixaban for Stroke Prevention in Non-valvular Atrial Fibrillation. Cardiol Ther. 2016 Dec;5(2):171–186. DOI:10.1007/s40119-016-0066-2.
   PubMed Web of Science ®Google Scholar
• López-López JA, Sterne JAC, Thom HHZ, et al. Oral anticoagulants for prevention of stroke in atrial fibrillation: systematic review, network meta-analysis, and cost effectiveness analysis. BMJ. 2017;28:359:j5058.
   Google Scholar
• Keeler E. Decision trees and Markov models in cost–effectiveness research. In: Sloan FA editor. Valuing Heal. Care Costs, Benefits, Eff. Pharm. Other Med. Technol. Cambridge University Press: Cambridge. 1995. 185–206. DOI:10.1017/CBO9780511625817.009.
   Google Scholar
• Caro JJ, Briggs AH, Siebert U, et al., Modeling Good Research Practices—Overview: A Report of the ISPOR-SMDM Modeling Good Research Practices Task Force-1. Value Health. 15(6): 796–803. 2012. DOI: 10.1016/j.jval.2012.06.012.
   PubMed Web of Science ®Google Scholar
• Walter E. Österreichische Guidelines zur gesundheitsökonomischen Evaluation [Guidelines for health-economic evaluations in Austria]. Pharmaco Econ Ger Res Art. 2006 Dec;4(2):55–63. German. DOI: 10.1007/BF03321566.
   Google Scholar
• Ruff CT, Giugliano RP, Braunwald E, et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet. 2014 Mar 15;383(9921):955–962.
   PubMed Web of Science ®Google Scholar
• Bundesministerium für Gesundheit (BMG). Vorhofflimmern: Bewusstsein schaffen zur Verlängerung der in Gesundheit verbrachten Lebensjahre [Atrial fibrillation: Create awareness to extend the years of life spent in health.]. In Abschlussbericht zur Enquete [Final report of the working conference]; Wien, Jänner; 2012. German.
   Google Scholar
• Connolly SJ, Ezekowitz MD, Yusuf S, et al. RE-LY Steering Committee and Investigators. Dabigatran versus Warfarin in Patients with Atrial Fibrillation. N Engl J Med. 2009;361:1139–1151.
   PubMed Web of Science ®Google Scholar
• Giugliano RP, Ruff CT, Braunwald E, et al. ENGAGE AF-TIMI 48 Investigators. Edoxaban versus Warfarin in Patients with Atrial Fibrillation. N Engl J Med. 2013;369:2093–2104.
   PubMed Web of Science ®Google Scholar
• Patel MR, Mahaffey KW, Garg J, et al. ROCKET AF Investigators. Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation. N Engl J Med. 2011;365:883–891.
   PubMed Web of Science ®Google Scholar
• Statistik Austria. Sterbetafel 2016 männlich und weiblich [Life table 2016 male and female]. Erstellt am 2017 Nov 5. German.
   Google Scholar
• Österreichischer Apothekerverlag. Warenverzeichnis I [Austrian classified index of goods I]. 2018 Aug. German.
   Google Scholar
• Belisari A, Iannazzo S, Pasquale GD, et al. Analisi di impatto sul budget SSN dell´impiego di idarucizumab nelle situazioni di emergenza/urgenza in pazienti in trattamento anticoagulante con dabigatran etexilato in Italia [Budget impact analysis of idarucizumab for the management of patients treated with dabigatran in emergency/urgent situations in Italy]. Farmeconomia. Health Econ Ther Pathways. 2016;17(2):47–58. Italian.
   Google Scholar
• European Medicines Agency (EMA). Product-information Praxbind. 2015 Nov 20. [Cited 2020 Feb 10]. https://www.ema.europa.eu/en/documents/product-information/praxbind-epar-product-information_en.pdf
   Google Scholar
• Burgenländische Gebietskrankenkasse (BGKK). Zusatzprotokoll zur Zusatzvereinbarung 2010/2011/2012 [Tariff catalogue 2010/2011/2012]. 2012. German.
   Google Scholar
• Kärntner Gebietskrankenkasse (KGKK). Honorarordnung 2016 [Tariff catalogue 2016]. 2016. German.
   Google Scholar
• Niederösterreichische Gebietskrankenkasse (NOEGKK). Honorarordnung 2015 [Tariff catalogue 2015]. 2015. German.
   Google Scholar
• Oberösterreichische Gebietskrankenkasse (OÖGKK). Arbeitsbehelf Honorarordnung für Ärzte für Allgemeinmedizin und Fachärzte [Tariff catalogue]. 2015. German.
   Google Scholar
• Salzburger Gebietskrankenkasse (SGKK). Honorartarif [Tariff catalogue]. 2016. German.
   Google Scholar
• Steiermärkische Gebietskrankenkasse (STGKK). Honorarordnung der Steiermärkischen Gebietskrankenkasse für Ärzte für Allgemeinmedizin und Fachärzte [Tariff catalogue]. 2015. German.
   Google Scholar
• Tiroler Gebietskrankenkasse (TGKK). Honorarordnung für Ärzte für Allgemeinmedizin und Fachärzte [Tariff catalogue]. 2016. German.
   Google Scholar
• Vorarlberger Gebietskrankenkasse (VGKK). Honorartarif für Vorarlberg [Tariff catalogue of Vorarlberg]. 2013. German.
   Google Scholar
• Wiener Gebietskrankenkasse (WGKK), Tarife für Vertragsärzte 2016 [Tariff catalogue 2016]. 2016. German.
   Google Scholar
• LKF. Leistungsorientierte Krankenanstaltenfinanzierung: Modell 2018 [System of procedure-oriented hospital financing: Model 2018]. 2018. German.
   Google Scholar
• Shepard DS. Cost-effectiveness in Health and Medicine. Gold MR, Siegel JE, Russell LB, et al., eds. New York: Oxford University Press; 1999.
   Google Scholar
• Berg J, Lindgren P, Nieuwlaat R, et al. Factors determining utility measured with the EQ-5D in patients with atrial fibrillation. Qual Life Res. 2010 Apr;19(3):381–390. DOI:10.1007/s11136-010-9591-y.
   PubMed Web of Science ®Google Scholar
• Robinson A, Thomson R, Parkin D, et al. How patients with atrial fibrillation value different health outcomes: a standard gamble study. J Health Serv Res Policy. 2001;6(2):92–98. DOI:10.1258/1355819011927288.
   PubMedGoogle Scholar
• Lenert L, Soetikno RM. Automated Computer Interviews to Elicit Utilities: Potential Applications in the Treatment of Deep Venous Thrombosis. J Am Med Inform Assoc. 1997;4(1):49–56.
   PubMed Web of Science ®Google Scholar
• Lacey E, Walters SJ. Continuing inequality: gender and social class influences on self perceived health after a heart attack. J Epidemiol Community Health. 2003;57(8):622–627.
   PubMed Web of Science ®Google Scholar
• Haacke C, Althaus A, Spottke A, et al. Long-Term Outcome After Stroke: Evaluating Health-Related Quality of Life Using Utility Measurements. Stroke. 2006;37(1):193–198. DOI:10.1161/01.STR.0000196990.69412.fb.
   PubMed Web of Science ®Google Scholar
• Lip GYH, Kongnakorn T, Phatak H, et al. Cost-effectiveness of apixaban versus other new oral anticoagulants for stroke prevention in atrial fibrillation. Clin Ther. 2014;36(2):192–210.e20. DOI:10.1016/j.clinthera.2013.12.011.
   PubMed Web of Science ®Google Scholar